Tivantinib二线治疗MET高表达晚期肝细胞癌的III期最终分析
METIV-HCC是一项在90个中心开展的III期随机双盲安慰剂对照研究,共纳入340例索拉非尼治疗后进展的MET高表达晚期肝细胞癌患者,按2:1随机接受tivantinib或安慰剂。最终分析显示两组中位总生存无显著差异,tivantinib未能改善总生存。
要点
- tivantinib组3级及以上治疗中出现的不良事件发生率为56%,与安慰剂组55%相近。
- 在晚期肝细胞癌患者中开展整体组织生物标志物研究是可行的。
核心结论
- 在既往接受索拉非尼治疗的MET高表达晚期肝细胞癌患者中,tivantinib相比安慰剂未改善总生存。
研究设计与样本
- III期随机双盲安慰剂对照研究,在澳大利亚、美洲、欧洲和新西兰的90个中心开展,共随机分配340例患者(tivantinib组226例,安慰剂组114例)。
主要发现
- tivantinib组3级及以上治疗中出现的不良事件发生于225例中的125例(56%),安慰剂组为114例中的63例(55%)。
- tivantinib组最常见的不良事件包括腹水16例(7%)、贫血11例(5%)、腹痛9例(4%)和中性粒细胞减少9例(4%)。
- tivantinib组226例中50例(22%)在末次给药后30天内死亡,安慰剂组114例中18例(16%);tivantinib组最常见死因为全身状况恶化8例(4%)和肝衰竭4例(2%)。
- tivantinib组225例中3例(1%)死于治疗相关不良事件(分别为脓毒症、贫血合并急性肾衰竭、急性冠脉综合征)。
临床怎么用
- 本研究为阴性结果,不支持在MET高表达晚期肝细胞癌二线治疗中常规使用tivantinib。
- 研究提示在晚期肝细胞癌中开展整体组织生物标志物研究具有可行性。
局限性
- 原文未系统列出本研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial. METHODS: We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, and New Zealand. Eligible patients were 18 years or older and had unresectable, histologically confirmed, hepatocellular carcinoma, an Eastern Cooperative Oncology Group performance status of 0-1, high MET expression (MET-high; staining intensity score ≥2 in ≥50% of tumour cells), Child-Pugh A cirrhosis, and radiographically-confirmed disease progression after receiving sorafenib-containing systemic therapy. We randomly assigned patients (2:1) in block sizes of three using a computer-generated randomisation sequence to receive oral tivantinib (120 mg twice daily) or placebo (twice daily); patients were stratified by vascular invasion, extrahepatic spread, and α-fetoprotein concentrations (≤200 ng/mL or >200 ng/mL). The primary endpoint was overall survival in the intention-to-treat population. Efficacy analyses were by intention to treat and safety analyses were done in all patients who received any amount of study drug. This study is registered with ClinicalTrials.gov, number NCT01755767. FINDINGS: Between Dec 27, 2012, and Dec 10, 2015, 340 patients were randomly assigned to receive tivantinib (n=226) or placebo (n=114). At a median follow-up of 18·1 months (IQR 14·1-23·1), median overall survival was 8·4 months (95% CI 6·8-10·0) in the tivantinib group and 9·1 months (7·3-10·4) in the placebo group (hazard ratio 0·97; 95% CI 0·75-1·25; p=0·81). Grade 3 or worse treatment-emergent adverse events occurred in 125 (56%) of 225 patients in the tivantinib group and in 63 (55%) of 114 patients in the placebo group, with the most common being ascites (16 [7%] patients]), anaemia (11 [5%] patients), abdominal pain (nine [4%] patients), and neutropenia (nine [4%] patients) in the tivantinib group. 50 (22%) of 226 patients in the tivantinib group and 18 (16%) of 114 patients in the placebo group died within 30 days of the last dose of study medication, and general deterioration (eight [4%] patients) and hepatic failure (four [2%] patients) were the most common causes of death in the tivantinib group. Three (1%) of 225 patients in the tivantinib group died from a treatment-related adverse event (one sepsis, one anaemia and acute renal failure, and one acute coronary syndrome). INTERPRETATION: Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib. Although this METIV-HCC trial was negative, the study shows the feasibility of doing integral tissue biomarker studies in patients with advanced hepatocellular carcinoma. Additional randomised studies are needed to establish whether MET inhibition could be a potential therapy for some subsets of patients with advanced hepatocellular carcinoma. FUNDING: ArQule Inc and Daiichi Sankyo (Daiichi Sankyo Group).
引用
- Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018. PMID: 29625879. doi:10.1016/S1470-2045(18)30146-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。